Clinical trial · Observational
Use of Fluorescence in Gliomas
Use of Fluorescence in High-Grade Gliomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
During brain tumor surgery, it can be difficult for surgeons to distinguish between tumor tissue and healthy brain tissue. To address this challenge, fluorescent agents such as sodium fluorescein or 5-ALA are sometimes used. These substances cause the tumor to "glow" under specific lighting conditions, making it easier to visualize. This study retrospectively analyzes medical records of patients treated at the University Hospital of Alessandria between June 2023 and March 2024. It compares surgeries performed with these fluorescent agents to those performed without them, in order to determine whether fluorescence-guided surgery leads to a higher rate of complete tumor removal (gross total resection), as confirmed by post-operative MRI scans. The aim is to evaluate how the use of fluorescent dyes (fluorochromes) influences surgical outcomes in patients with high-grade gliomas (aggressive brain tumors). The study will also assess the impact of these tools on operative time, patient safety, and the overall recovery process.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Neoplasms | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
| High Grade Glioma | High-Grade Glioma, NOS | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| data collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Fluorescence-Guided Surgery Group
- description
- This cohort includes patients who underwent neurosurgical resection with the aid of fluorescence-guided surgery. In these cases, fluorochromes (such as sodium fluorescein and/or 5-aminolevulinic acid \[5-ALA\]) were used to enhance intraoperative visualization of tumor tissue and facilitate its resection
- interventionNames
- Other: data collection
- label
- Conventional Surgery Group
- description
- This cohort includes patients who underwent neurosurgical tumor resection using standard microsurgical techniques without the use of fluorochromes. Tumor removal was performed based on anatomical and neuroradiological information and the surgeon's expertise, without fluorescence guidance.
- interventionNames
- Other: data collection
Primary outcomes (1)
- measure
- Evaluate the extent of tumor mass resection
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients hospitalized at the AOU AL (Neurosurgery Department) and undergoing surgical removal of a brain lesion compatible with ICD-9 diagnosis: * 191 MALIGNANT TUMORS OF THE BRAIN * 191.1 MALIGNANT TUMORS OF THE FRONTAL LOBE * 191.2 MALIGNANT TUMORS OF THE TEMPORAL LOBE * 191.3 MALIGNANT TUMORS OF THE PARIETAL LOBE * 191.4 MALIGNANT TUMORS OF THE OCCIPITAL LOBE * 191.9 MALIGNANT TUMORS OF THE BRAIN, UNSPECIFIED * Signing of informed consent Exclusion Criteria: * Incomplete electronic records or missing clinical data useful for this study. * Patients not eligible for surgical intervention * Patients affected by a neoplasm not compatible with a histological diagnosis of high-grade glioma
References
Publications (0)
Data not yet available